Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial

• Published in: The lancet oncology 2024-10, Vol.25 (10), p.1288-1297
• Main Authors: Peng, Zikun, Li, Huayi, Gao, Yunong, Sun, Li, Jiang, Jie, Xia, Bairong, Huang, Yi, Zhang, Yu, Xia, Yu, Zhang, Yuxin, Shen, Yiyang, Huang, Bowen, Nie, Jiayu, Chen, Xinrong, Liu, Xingyu, Feng, Cui, Li, Zhen, Zhang, Wei, Tao, Kangjia, Zhang, Qiuxue, Duan, Shican, Chen, Yaheng, Chen, Yeshan, Wang, Wei, Zheng, Hong, Lu, Yudong, Liu, Yi, Wang, Limei, Qi, Wencai, He, Yang, Tian, Yan, Hu, Ting, Zeng, Shaoqing, Wang, Ya, Chi, Jianhua, Jiao, Xiaofei, Liu, Jiahao, Li, Ming, Wen, Yuanjia, Xiong, Fan, Xu, Yu, Ma, Guanchen, Zhao, Yingjun, Yu, Yang, Li, Ruyuan, Li, Guiling, Ma, Ding, Gao, Qinglei
• Format: Article
• Language: English
• Subjects: Adverse events; Angiogenesis; Bevacizumab; Chemotherapy; Clinical trials; Disease; Heart diseases; Hypoxia; Immunotherapy; Monoclonal antibodies; Myocarditis; Oncology; Ovarian cancer; Ovarian carcinoma; Patients; Proteinuria; Renal function; Response rates; Solid tumors; Targeted cancer therapy; Toxicity; Translation; Tumors
• ISSN: 1470-2045; 1474-5488; 1474-5488
• DOI: 10.1016/S1470-2045(24)00437-6

Ovarian clear cell carcinoma rarely responds to second-line chemotherapy, the recommended treatment for relapsed epithelial ovarian cancer. Here, we report the activity and safety of sintilimab in combination with bevacizumab in patients with relapsed or persistent ovarian clear cell carcinoma. In the prospective, multicentre, single-arm, phase 2 INOVA trial, patients aged 18–75 years with histologically confirmed relapsed or persistent ovarian clear cell carcinoma were enrolled from eight tertiary hospitals in China. Eligible patients had an Eastern Cooperative Oncology Group performance status score of 0–2 and previous exposure to at least one cycle of platinum-containing chemotherapy. Enrolled patients received sintilimab (200 mg) and bevacizumab (15 mg/kg) intravenously every 3 weeks until disease progression. The primary endpoint was objective response rate assessed by independent central review based on Response Evaluation Criteria in Solid Tumours version 1.1. Eligible enrolled patients who received at least one cycle of treatment and had at least one tumour response assessment following the baseline assessment per protocol were included in the activity analysis. Patients who received at least one dose of study drug were included in the safety analysis. The study is registered with ClinicalTrials.gov (NCT04735861) and is ongoing. Between April 8, 2021, and July 3, 2023, 51 patients were screened and 41 patients received at least one dose of sintilimab in combination with bevacizumab. Response evaluation was completed in 37 patients. Objective responses were observed in 15 patients (objective response rate 40·5%; 95% CI 24·8–57·9), of which five (14%) were complete responses and ten (27%) were partial responses. At data cutoff (Jan 29, 2024), the median follow-up was 16·9 months (IQR 7·5–23·4). Three (7%) patients developed grade 3 treatment-related adverse events including one patient with proteinuria, one patient with myocarditis, and one patient with rash. No treatment-related adverse events of worse than grade 3 severity were recorded. Treatment-related serious adverse events occurred in two (5%) patients including one patient with immune-related myocarditis and another with hypertension and renal dysfunction. No treatment-related deaths occurred. Sintilimab in combination with bevacizumab showed promising anti-tumour activity and manageable safety in patients with relapsed or persistent ovarian clear cell carcinoma. Larger, randomised trials are